Risk of Kidney Failure and Mortality in Patients With ANCA-Associated Vasculitis Treated With Rituximab- vs Cyclophosphamide-Based Remission Induction Strategies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Comparative Effectiveness of Rituximab- vs Cyclophosphamide-Based Remission Induction Strategies in ANCA-Associated Vasculitis for the Risk of Kidney Failure and Mortality
Arthritis Rheumatol 2023 Apr 03;[EPub Ahead of Print], ZS Wallace, X Fu, C Cook, C Ahola, Z Williams, B Doliner, JS Hanberg, JH Stone, Y Zhang, HK ChoiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.